about
Loss of AXIN1 drives acquired resistance to WNT pathway blockade in colorectal cancer cells carrying RSPO3 fusionsTumor Heterogeneity and Lesion-Specific Response to Targeted Therapy in Colorectal Cancer.Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer.Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer.Emergence of Multiple EGFR Extracellular Mutations during Cetuximab Treatment in Colorectal Cancer.Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor.Tracking colorectal cancer evolution in time and space.Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases.Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal CancerErratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patientsWhole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patientsAdaptive mutability of colorectal cancers in response to targeted therapiesA Genomic Analysis Workflow for Colorectal Cancer Precision Oncology
P50
Q37672680-8ACAD65B-A1E2-4E1C-89D4-F4AFB0DE700FQ38275060-3609BC43-A44D-470E-86A2-0D82F8A2D088Q38706872-5284B0C5-9C71-41A3-9191-6FDE214376E4Q38764035-3FAEB836-6D7C-425F-B90B-871AC545D04BQ38821392-4DFB3787-C96A-451B-8ABC-340F146F649BQ38916276-4122641E-A221-4CBD-A979-F6E235654583Q39120801-05426CFB-4DB9-4BCD-9834-6E71935FCF85Q42183079-ACC2BA90-334B-45E0-B531-0A5D60F31206Q42689844-405DEF52-A5EF-4BA1-AEF1-A5AD2AD478D2Q48562035-C75FCC03-3FA4-4D58-AD4B-2C1105498421Q48562940-990A7FFE-38D2-4684-B7EE-F3563F04816BQ49551908-74387C89-ED9E-47F0-984D-E2A0A07CD421Q55100041-E4AA990C-26F4-4080-93B8-007CAD8DE644Q57280543-FD8B1D41-FC45-4A7C-9F9C-D3D56CA3F218Q57280718-4F27C047-4032-4950-BE3C-801BEF096354Q90156140-6343E9DB-9C3C-48EB-94F5-CA498785B50AQ91172844-16E8B030-10AA-4FA8-A545-80571041B0FBQ93074969-7A244E26-E907-42B0-B656-99E136F7EAFE
P50
description
researcher ORCID ID = 0000-0002-5511-1555
@en
wetenschapper
@nl
name
Giovanni Crisafulli
@ast
Giovanni Crisafulli
@en
Giovanni Crisafulli
@es
Giovanni Crisafulli
@nl
type
label
Giovanni Crisafulli
@ast
Giovanni Crisafulli
@en
Giovanni Crisafulli
@es
Giovanni Crisafulli
@nl
prefLabel
Giovanni Crisafulli
@ast
Giovanni Crisafulli
@en
Giovanni Crisafulli
@es
Giovanni Crisafulli
@nl
P1153
55506977900
P21
P31
P496
0000-0002-5511-1555